SLCO2A1: A Potential Drug Target for Psychiatric Disorders (G6578)

Target Name: SLCO2A1

NCBI ID: G6578

SLCO2A1

SLCO2A1: A Potential Drug Target for Psychiatric Disorders

Prostaglandin (PG) is a naturally occurring lipid-soluble neurotransmitter that plays a crucial role in various physiological processes in the body, including pain signaling, inflammation, and blood pressure regulation. The PG transporter gene, SLCO2A1, has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders.

SLCO2A1 is a member of the selective cation transport family 2 (SLCO2A), which includes several genes involved in the transport of various anions, including protons, electrons, and solutes across cell membranes. The SLCO2A1 gene is located on chromosome 12q14 and encodes a protein that is expressed in various tissues and organs, including the brain, heart, kidney, and intestine.

The PG transporter is a protein that plays a critical role in the regulation of PG signaling. It is a transmembrane protein that consists of an intrachellular loop, a catalytic domain, and an extracellular region. The intracellular loop is the region where the protein interacts with various intracellular signaling molecules, while the catalytic domain is responsible for the protein's catalytic activity. The extracellular region is involved in the protein's interactions with ligands and other proteins in the cell membrane.

SLCO2A1 is involved in the regulation of PG signaling by controlling the movement of PGs across the cell membrane. PGs can interact with SLCO2A1 to either activate or inhibit their signaling potential. Activated PGs can cause various cellular responses, including the production of reactive oxygen species (ROS), inflammation, and neurotoxicity. In contrast, inhibited PGs can have a neuroprotective effect by modulating inflammation, pain perception, and neuroplasticity.

SLCO2A1 has been implicated in several psychiatric and neurological disorders, including anxiety, depression, and neurodegenerative diseases. Studies have shown that individuals with certain genetic variations in the SLCO2A1 gene are at increased risk for developing these disorders. For example, individuals with a specific genetic variation (SNP) in the SLCO2A1 gene have been shown to have an increased risk of developing major depressive disorder (MDD).

In addition to its potential role in psychiatric disorders, SLCO2A1 has also been implicated in several other neurological disorders, including pain, inflammation, and neurodegenerative diseases. For example, SLCO2A1 has been shown to be involved in the regulation of pain signaling, and individuals with SLCO2A1 genetic variations may be more susceptible to chronic pain. Additionally, SLCO2A1 has been linked to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

SLCO2A1 is also a potential biomarker for these disorders, as its expression levels can be affected by various factors, including genetic variations, drugs, and diseases. For example, individuals with certain genetic variations in the SLCO2A1 gene may have reduced levels of SLCO2A1 protein, which could make them more susceptible to the effects of drugs that target this protein. Additionally, SLCO2A1 levels can be affected by various diseases, such as neurodegenerative diseases, which could impact its expression and contribute to the development of these conditions.

In conclusion, SLCO2A1 is a gene that has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders. Its role in the regulation of PG signaling and its involvement in the development of various disorders make it an attractive target for drug development. Further research is needed to fully understand the role of SLCO2A1 in the regulation of PG signaling and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Organic Anion Transporter Family Member 2A1

Functions: Mediates the transport of prostaglandins (PGs, mainly PGE2, PGE1, PGE3, PGF2alpha, PGD2, PGH2) and thromboxanes (thromboxane B2) across the cell membrane (PubMed:8787677, PubMed:11997326, PubMed:26692285). PGs and thromboxanes play fundamental roles in diverse functions such as intraocular pressure, gastric acid secretion, renal salt and water transport, vascular tone, and fever (PubMed:15044627). Plays a role in the clearance of PGs from the circulation through cellular uptake, which allows cytoplasmic oxidation and PG signal termination (PubMed:8787677). PG uptake is dependent upon membrane potential and involves exchange of a monovalent anionic substrate (PGs exist physiologically as an anionic monovalent form) with a stoichiometry of 1:1 for divalent anions or of 1:2 for monovalent anions (PubMed:29204966). Uses lactate, generated by glycolysis, as a counter-substrate to mediate PGE2 influx and efflux (PubMed:11997326). Under nonglycolytic conditions, metabolites other than lactate might serve as counter-substrates (PubMed:11997326). Although the mechanism is not clear, this transporter can function in bidirectional mode (PubMed:29204966). When apically expressed in epithelial cells, it facilitates transcellular transport (also called vectorial release), extracting PG from the apical medium and facilitating transport across the cell toward the basolateral side, whereupon the PG exits the cell by simple diffusion (By similarity). In the renal collecting duct, regulates renal Na+ balance by removing PGE2 from apical medium (PGE2 EP4 receptor is likely localized to the luminal/apical membrane and stimulates Na+ resorption) and transporting it toward the basolateral membrane (where PGE2 EP1 and EP3 receptors inhibit Na+ resorption) (By similarity). Plays a role in endometrium during decidualization, increasing uptake of PGs by decidual cells (PubMed:16339169). Involved in critical events for ovulation (PubMed:27169804). Regulates extracellular PGE2 concentration for follicular development in the ovaries (By similarity). Expressed intracellularly, may contribute to vesicular uptake of newly synthesized intracellular PGs, thereby facilitating exocytotic secretion of PGs without being metabolized (By similarity). Essential core component of the major type of large-conductance anion channel, Maxi-Cl, which plays essential roles in inorganic anion transport, cell volume regulation and release of ATP and glutamate not only in physiological processes but also in pathological processes (By similarity). May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

The "SLCO2A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLCO2A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets